DK1848813T3 - Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-celler - Google Patents
Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-cellerInfo
- Publication number
- DK1848813T3 DK1848813T3 DK06733921.8T DK06733921T DK1848813T3 DK 1848813 T3 DK1848813 T3 DK 1848813T3 DK 06733921 T DK06733921 T DK 06733921T DK 1848813 T3 DK1848813 T3 DK 1848813T3
- Authority
- DK
- Denmark
- Prior art keywords
- cd1d
- activation
- nkt cells
- restricted nkt
- bacterial glycolipid
- Prior art date
Links
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 title 1
- 229930186217 Glycolipid Natural products 0.000 title 1
- 230000004913 activation Effects 0.000 title 1
- 230000001580 bacterial effect Effects 0.000 title 1
- 210000000581 natural killer T-cell Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64815305P | 2005-01-28 | 2005-01-28 | |
| PCT/US2006/002781 WO2006083671A2 (en) | 2005-01-28 | 2006-01-26 | Bacterial glycolipid activation of cd1d-restricted nkt cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1848813T3 true DK1848813T3 (da) | 2013-07-15 |
Family
ID=36777772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06733921.8T DK1848813T3 (da) | 2005-01-28 | 2006-01-26 | Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-celler |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9295722B2 (https=) |
| EP (1) | EP1848813B1 (https=) |
| JP (1) | JP5053101B2 (https=) |
| AU (1) | AU2006211485B2 (https=) |
| BR (1) | BRPI0607299A2 (https=) |
| CA (1) | CA2593715C (https=) |
| DK (1) | DK1848813T3 (https=) |
| ES (1) | ES2423005T3 (https=) |
| PL (1) | PL1848813T3 (https=) |
| PT (1) | PT1848813E (https=) |
| WO (1) | WO2006083671A2 (https=) |
| ZA (1) | ZA200706208B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645873B2 (en) | 2003-03-20 | 2010-01-12 | The Scripps Research Institute | 6″-amino-6″-deoxygalactosylceramides |
| PL2056842T3 (pl) | 2006-04-07 | 2013-03-29 | Scripps Research Inst | Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych |
| AU2007269299B2 (en) | 2006-06-30 | 2013-01-17 | Brigham Young University | Adjuvants and methods of use |
| JP2010523724A (ja) * | 2007-04-13 | 2010-07-15 | アカデミア シニカ | α−ガラクトシルセラミド類似体およびそれらの免疫療法剤としての使用 |
| US8916164B2 (en) | 2007-08-29 | 2014-12-23 | Abivax | Methods of enhancing adjuvaticity of vaccine compositions |
| EP2058011A1 (en) | 2007-11-07 | 2009-05-13 | Wittycell | Nkt cell activating gycolipids covalently bound antigens and/or drug |
| AU2013202865B2 (en) * | 2007-11-07 | 2015-03-19 | Abivax | Increase of immune response and targeting by antigens and/or drug linkage |
| EP2060252A1 (en) | 2007-11-19 | 2009-05-20 | Wittycell | New formulation of galactosylceramide derivatives |
| US8207135B2 (en) | 2007-12-05 | 2012-06-26 | Wittycell | Compositions for and methods of enhancing the immune response to antigens |
| JP5809560B2 (ja) | 2008-10-08 | 2015-11-11 | アビヴァックス | インフルエンザに対して使用するためのワクチン組成物 |
| WO2010097700A1 (en) | 2009-02-25 | 2010-09-02 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| US8383663B2 (en) | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| CA2893918C (en) * | 2012-12-06 | 2020-11-24 | Callaghan Innovation Research Limited | Conjugate compounds |
| US9580758B2 (en) | 2013-11-12 | 2017-02-28 | Luc Montagnier | System and method for the detection and treatment of infection by a microbial agent associated with HIV infection |
| CN115666586A (zh) * | 2020-04-23 | 2023-01-31 | 加州大学评议会 | 通过激活iNKT细胞清除衰老细胞 |
| FR3117776B1 (fr) * | 2020-12-18 | 2024-03-08 | Oreal | Extrait de bactérie du genreSphingomonas |
| EP4262997A1 (en) * | 2020-12-18 | 2023-10-25 | L'oreal | Extract of bacteria of the genus sphingomonas |
| CN117222414A (zh) | 2021-03-01 | 2023-12-12 | 脱落性治疗公司 | 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法 |
| WO2024107463A1 (en) * | 2022-11-14 | 2024-05-23 | The Trustees Of Columbia University In The City Of New York | 7dw8-5 treatment for covid-19 and other virus-induced respiratory infections |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| TW261533B (https=) | 1992-07-16 | 1995-11-01 | Kirin Brewery | |
| EP0666268B1 (en) | 1992-10-22 | 2000-04-19 | Kirin Beer Kabushiki Kaisha | Novel sphingoglycolipid and use thereof |
| EP0694558B1 (en) | 1993-04-15 | 1999-01-27 | Kirin Beer Kabushiki Kaisha | Novel sphingoglycolipid and use thereof |
| RO117533B1 (ro) | 1993-05-14 | 2002-04-30 | Cytel Corp San Diego | DERIVATI DE ANALOGI SIALIL LeX INHIBITORI AI ADEZIUNII CELULARE SI COMPOZITIE FARMACEUTICA CU ACESTIA |
| ATE286735T1 (de) | 1997-04-10 | 2005-01-15 | Kirin Brewery | Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten |
| JP2001515868A (ja) * | 1997-09-12 | 2001-09-25 | ブライハム アンド ウイメンズ ホスピタル | Ｃｄ１制限免疫応答のための合成抗原 |
| AU2001252599A1 (en) | 2000-04-28 | 2001-11-12 | Orient Cancer Therapy Co., Ltd. | Remedies for cancer |
| AU2002213588A1 (en) * | 2000-06-05 | 2001-12-17 | The Brigham And Women's Hospital, Inc. | Soluble cd1 compositions and uses thereof |
| DK2336187T3 (en) * | 2000-06-19 | 2016-08-22 | Beth Israel Deaconess Medical Ct Inc | Compositions and Methods of monoclonal and polyclonal antibodies which are specific for T-cell subpopulations |
| WO2001098317A2 (en) * | 2000-06-22 | 2001-12-27 | The Brigham And Women's Hospital, Inc. | Alpha-glycosylceramides for treating bacterial and fungal infections |
| CN1561389A (zh) * | 2001-07-25 | 2005-01-05 | 纽约大学 | 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途 |
| KR100549866B1 (ko) * | 2001-08-22 | 2006-02-08 | 고려대학교 산학협력단 | 암치료 및 예방 제제 |
| CN1578667A (zh) | 2001-11-06 | 2005-02-09 | 东方癌症治疗株式会社 | 抗癌组合物 |
| WO2003105769A2 (en) * | 2002-06-13 | 2003-12-24 | New York University | Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| WO2004094444A1 (en) | 2003-03-20 | 2004-11-04 | Brigham Young University | 6'-amino-6'-deoxygalactosylceramides |
| US7645873B2 (en) | 2003-03-20 | 2010-01-12 | The Scripps Research Institute | 6″-amino-6″-deoxygalactosylceramides |
| GB0314682D0 (en) | 2003-06-24 | 2003-07-30 | Isis Innovation | Materials and methods relating to the modulation of T cell response to soluble antigen |
| JP5005541B2 (ja) | 2004-09-03 | 2012-08-22 | ザ ユニヴァーシティー オヴ シカゴ | Ｎｋｔ細胞の活性化方法 |
| PL2056842T3 (pl) | 2006-04-07 | 2013-03-29 | Scripps Research Inst | Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych |
| AU2007269299B2 (en) | 2006-06-30 | 2013-01-17 | Brigham Young University | Adjuvants and methods of use |
-
2006
- 2006-01-26 CA CA2593715A patent/CA2593715C/en not_active Expired - Fee Related
- 2006-01-26 ES ES06733921T patent/ES2423005T3/es not_active Expired - Lifetime
- 2006-01-26 PL PL06733921T patent/PL1848813T3/pl unknown
- 2006-01-26 DK DK06733921.8T patent/DK1848813T3/da active
- 2006-01-26 AU AU2006211485A patent/AU2006211485B2/en not_active Ceased
- 2006-01-26 WO PCT/US2006/002781 patent/WO2006083671A2/en not_active Ceased
- 2006-01-26 BR BRPI0607299-2A patent/BRPI0607299A2/pt not_active IP Right Cessation
- 2006-01-26 PT PT67339218T patent/PT1848813E/pt unknown
- 2006-01-26 JP JP2007553225A patent/JP5053101B2/ja not_active Expired - Fee Related
- 2006-01-26 EP EP06733921.8A patent/EP1848813B1/en not_active Expired - Lifetime
- 2006-01-26 US US11/814,103 patent/US9295722B2/en not_active Expired - Fee Related
-
2007
- 2007-07-26 ZA ZA200706208A patent/ZA200706208B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1848813A4 (en) | 2008-07-09 |
| US9295722B2 (en) | 2016-03-29 |
| ES2423005T3 (es) | 2013-09-17 |
| AU2006211485B2 (en) | 2011-04-14 |
| PT1848813E (pt) | 2013-07-15 |
| US20080279894A1 (en) | 2008-11-13 |
| EP1848813B1 (en) | 2013-04-10 |
| CA2593715C (en) | 2015-05-05 |
| WO2006083671A2 (en) | 2006-08-10 |
| AU2006211485A1 (en) | 2006-08-10 |
| WO2006083671B1 (en) | 2007-04-12 |
| CA2593715A1 (en) | 2006-08-10 |
| PL1848813T3 (pl) | 2013-09-30 |
| EP1848813A2 (en) | 2007-10-31 |
| BRPI0607299A2 (pt) | 2009-08-25 |
| ZA200706208B (en) | 2008-04-30 |
| JP5053101B2 (ja) | 2012-10-17 |
| JP2008528608A (ja) | 2008-07-31 |
| WO2006083671A3 (en) | 2007-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1848813T3 (da) | Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-celler | |
| EP2178460A4 (en) | cartilage transplants | |
| PL2634242T3 (pl) | Ulepszony sposób hodowli komórek | |
| BRPI0816613A2 (pt) | novos derivados de oligossacarideos sulfatados | |
| BRPI0716881A2 (pt) | Composições tópicas | |
| BRPI0716762A2 (pt) | melhorias da cultura celular | |
| DE602006011777D1 (de) | Acrylhaftklebstoffzusammensetzung für polarisationsfolie | |
| CR9902A (es) | Drrivados de amida heterociclica utiles como microbiocidas | |
| EP1958592A4 (en) | intraocular lens | |
| EP2154906A4 (en) | SPEAKER SYSTEM | |
| EP2003722A4 (en) | STACK CELL | |
| DK1913135T3 (da) | Extracellulære polyhydroxyalkanoater frembragt af genetisk modificerede mikroorganismer | |
| DK2139936T3 (da) | Polyurethansammensætning indeholdende asymmetrisk dialdimin | |
| EP2245546A4 (en) | ASYNCHRONOUS REPLICATION | |
| EP2083933A4 (en) | IMPROVED MEMBRANE MODULE | |
| DK2027150T3 (da) | Allo-begrænsede peptid-specifikke t-celler | |
| DE602007008627D1 (de) | Zellkulturmedium | |
| BRPI0813726A2 (pt) | Célula de lítio | |
| EP1937307A4 (en) | SPECIFIC REMOVAL OF ACTIVATED IMMUNOCELLS | |
| DK1838295T3 (da) | Anthelmintisk sammensætning | |
| EP2136823A4 (en) | TELECENTAL GLIAL RESTRICTED CELL POPULATIONS AND ASSOCIATED COMPOSITIONS AND METHOD | |
| DE602006004859D1 (de) | Flüssigkristallines polymer enthaltende zusammensetzung | |
| FR2917971B1 (fr) | Composition amincissante | |
| DE502008000917D1 (de) | Lautsprecherbox | |
| SI1848813T1 (sl) | Aktiviranje bakterijskega glikopida s CD1D omenjenih NKT-celic |